Industries > Pharma > Top 30 Oncology Drugs Manufacturers 2019

Top 30 Oncology Drugs Manufacturers 2019

AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies

PUBLISHED: 03 May 2019
PAGES: 157
PRODUCT CODE: PHA0417
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0417 Categories: , Tags: , , , , ,

Cancer treating drugs market forms the most lucrative sector in pharmaceuticals. As the ageing population continues to rise across the world, the incidence of cancer will continue to grow, leading to increased spending on cancer-treating medicines. This report lists and discusses the top 30 oncology drugs manufacturers.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 157-page report you will receive 83 tables and 64 figures–all unavailable elsewhere.

The 157-page report provides clear detailed insight into the top 30 oncology drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Assessment of the leading companies in the global oncology drugs market. The list below shows some of the companies that are discussed in the report:
• Abbott Laboratories
• AbbVie
• Amgen
• Astellas Pharma
• AstraZeneca
• Aurora Biophama
• Boehringer Ingelheim
• Bristol-Myers Squibb (BMS)
• Celgene Corporation
• Eli Lilly
• Fresenius Kabi
• Gilead
• GlaxoSmithKline (GSK)
• Grifols
• Johnson & Johnson
• Jounce Therapeutics
• Other companies

Top 30 Oncology Drugs Manufacturers 2019

• For each company, the report provides information and discussion on:
• Company overview
• Product portfolio
• Recent development
• Financial information

• Key questions answered by this report:
• How is the Oncology Drugs Manufacturers market evolving?
• What is driving and restraining the Oncology Drugs Manufacturers market?
• What will be the main driver for the overall market?
• Will leading Oncology Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?

Visiongain’s study is intended for anyone requiring commercial analyses for the Top 30 Oncology Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 30 Oncology Drugs Manufacturers 2019: AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Top 30 Oncology Drugs Manufacturers 2019


Download sample pages

Complete the form below to download your free sample pages for Top 30 Oncology Drugs Manufacturers 2019


Latest Pharma news

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

READ

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

READ

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

READ

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

READ

Categories

Category